Tratamientos
CONTROL OF SYMPTOMS AND SAFETY WITH THE ADMINISTRATION OF PALIPERIDONE PALMITATE 3-MONTH FORMULATION

CONTROL OF SYMPTOMS AND SAFETY WITH THE ADMINISTRATION OF PALIPERIDONE
PALMITATE 3-MONTH FORMULATION
José Ángel Alcalá Partera, Ana Belén Rico del Viejo, Juan Luis Prados Ojeda
Reina Sofia University Hospital. Dept. of Mental Health. Córdoba. Spain.
13th Wold Congress of Biological Psychiatry. 18-22 June 2017. Copenhagen. Denmark.

OBJECTIVES:
The appearance of paliperidone palmitate for quarterly use is an extraordinary advance and novelty from a pharmacokinetic point of view. This treatment may be
initiated in patients who are adequately treated with the monthly use formulation for at least 4 months and not require dose adjustment at this time interval.
The objectives of this study are to quantify short- and long-term changes in the symptoms control and patient safety profile.

METHODOLOGY:
Descriptive cross-sectional and longitudinal prospective study of multicenter follow-up, in the population area corresponding to several community mental health
units.
Selection criteria:
-Patients initiating the administration of quarterly injectable paliperidone palmitate.
-Patients who initiate the administration of monthly paliperidone injectable palmitate for at least 4 months and without requiring dose adjustment at this time.
-Age between 18 and 65 years.
-Informed consent.
Exclusion criteria:
- Existence of important cognitive or sensory deficits.
- Recent admission in psychiatric hospitalization unit.
- Receive change of antipsychotic or antidepressant medication in the last month.

Twuelve patients receiving paliperidone palmitate injection for quartely use, who met inclusion criteria at the baseline visit and weeks number 12 and 24 were
analyzed. The data collection notebook consists of three distinct parts:
1. Sociodemographic variables: sex, age, marital status, occupation and main family.
2. Clinical variables: data are collected regarding the diagnosis of the disease, years of evolution, other drugs and associated toxic consumption.
3. Clinical scales: Brief Psychiatric Assessment Scale (BPRS), Global clinical impression scale (CGI), Short test of functionality evaluation (FAST), Subjective wellbeing scale with neuroleptics (SWN-K) and Barrowclough and Tarrier Family Questionnaire (TQ).
A basic descriptive statistic was carried out, using for the quantitative variables the calculation of the mean and standard deviation and for the qualitative variables
the distribution of absolute and relative frequencies. Twelve outpatients were included: fifty percent with paliperidone palmitate inyection 100mg monthly and fifty
percent with 150 mg monthly. Also nine patients were medicated with oral antipsychotics.

RESULTS:

Table 1

Graphic 1: score on SWN-K scale
SCALE

Baseline visit

12th week

24th week

BPRS

37±3,24

36±5,28

36±6,76

CGI

5±0,5

5±0,5

5±0,5

FAST

49±4,78

47±4,72

46±5,36

SWN-K

80,3±5,60

86,7±8,60*

87,8±9,60*

TQ

20±0,5

46±1,22*

46±1,80*

Graphic 2: score on TQ questionnaire

*P<0,05

CONCLUSIONS:
1. Our population sample of patients receiving quarterly paliperidone injectable palmitate medication were clinically stable
without tolerance problems at 12 and 24 months.
2. These patients and their relatives present high levels of satisfaction with the administration of paliperidone injectable
quarterly at 12 and 24 weeks.

REFERENCES:
1. Awad AG, Voruganti LN. The impact of newer atypical antipsychotics on patient-reported outcomes in schizophrenia. CNS drugs. 2013; 27:625­636.
2. Mohamed S, Rosenheck R, McEvoy J, Swartz M, Stroup S, Lieberman JA. Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical
outcomes in chronic schizophrenia. Schizophr Bull. 2009; 35:336­346.
3. Ravenstijn P, Remmerie B, Savitz A, et al. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose,
randomized, open-label study. J Clin Pharmacol. 2016;56(3):330­339.



IMPORTANTE: Algunos textos de esta ficha pueden haber sido generados partir de PDf original, puede sufrir variaciones de maquetación/interlineado, y omitir imágenes/tablas.